INS and type 2 diabetes mellitus: The hallmark of type 2 diabetes progression is the progressive decline of pancreatic beta-cell mass and secretory function with subsequent worsening glycaemia, secondary oral hypoglycaemic agent failure, and initiation of insulin therapy [2, 3].